JP2020005504A - 脂肪蓄積抑制用組成物 - Google Patents
脂肪蓄積抑制用組成物 Download PDFInfo
- Publication number
- JP2020005504A JP2020005504A JP2018126545A JP2018126545A JP2020005504A JP 2020005504 A JP2020005504 A JP 2020005504A JP 2018126545 A JP2018126545 A JP 2018126545A JP 2018126545 A JP2018126545 A JP 2018126545A JP 2020005504 A JP2020005504 A JP 2020005504A
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- chain fatty
- medium
- acid glyceride
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 149
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 59
- 229930195729 fatty acid Natural products 0.000 claims abstract description 59
- 239000000194 fatty acid Substances 0.000 claims abstract description 59
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 46
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 43
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 42
- 150000002576 ketones Chemical class 0.000 claims abstract description 41
- 235000019786 weight gain Nutrition 0.000 claims abstract description 34
- 239000000470 constituent Substances 0.000 claims abstract description 32
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims description 56
- 238000009825 accumulation Methods 0.000 claims description 43
- 208000008589 Obesity Diseases 0.000 claims description 40
- 235000020824 obesity Nutrition 0.000 claims description 40
- 230000004584 weight gain Effects 0.000 claims description 32
- 239000007787 solid Substances 0.000 claims description 27
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 26
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 15
- 235000019577 caloric intake Nutrition 0.000 claims description 12
- 235000016709 nutrition Nutrition 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 6
- 235000013341 fat substitute Nutrition 0.000 claims 1
- 239000003778 fat substitute Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 17
- 230000037396 body weight Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 239000003925 fat Substances 0.000 description 72
- 235000019197 fats Nutrition 0.000 description 72
- 238000002360 preparation method Methods 0.000 description 69
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 41
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 29
- 235000005911 diet Nutrition 0.000 description 27
- 230000037213 diet Effects 0.000 description 26
- 235000012054 meals Nutrition 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 230000037406 food intake Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 16
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 15
- 108010046377 Whey Proteins Proteins 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 102000007544 Whey Proteins Human genes 0.000 description 12
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 108010076119 Caseins Proteins 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000021590 normal diet Nutrition 0.000 description 10
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 10
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 235000021119 whey protein Nutrition 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 235000021195 test diet Nutrition 0.000 description 7
- 238000001061 Dunnett's test Methods 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 210000000593 adipose tissue white Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000008157 edible vegetable oil Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 235000003441 saturated fatty acids Nutrition 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940071162 caseinate Drugs 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 235000021056 liquid food Nutrition 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 229940080237 sodium caseinate Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- QACUPNAKIPYZAW-RMQWDSPGSA-N O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QACUPNAKIPYZAW-RMQWDSPGSA-N 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- -1 glycerol Long chain fatty acid triglycerides Chemical group 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JLRBNGCMXSGALP-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O.CCCCCCC(O)=O JLRBNGCMXSGALP-UHFFFAOYSA-N 0.000 description 1
- ZILMEHNWSRQIEH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O.CCCCCC(O)=O ZILMEHNWSRQIEH-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 231100000551 menstrual abnormality Toxicity 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- BMQNWLUEXNQIGL-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O.CCCCCCCCC(O)=O BMQNWLUEXNQIGL-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pediatric Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Abstract
Description
[1]炭素数8の飽和脂肪酸を構成脂肪酸として含む中鎖脂肪酸グリセリドを有効成分として含んでなる、脂肪蓄積抑制用、体重増加抑制用および/またはケトン体生成促進用組成物並びに脂肪蓄積抑制剤、体重増加抑制剤および/またはケトン体生成促進剤。
[2]前記中鎖脂肪酸グリセリドの中鎖脂肪酸総量に対する炭素数8の飽和脂肪酸量の比率(質量比、固形分換算)が、0.6以上である、上記[1]に記載の組成物および用剤。
[3]前記中鎖脂肪酸グリセリドが、炭素数10の飽和脂肪酸および/または炭素数12の飽和脂肪酸を構成脂肪酸としてさらに含む、上記[1]または[2]に記載の組成物および用剤。
[4]前記中鎖脂肪酸グリセリドを、1日当たり3g以上(固形分換算)の量で対象に摂取させる、上記[1]〜[3]のいずれかに記載の組成物および用剤。
[5]前記中鎖脂肪酸グリセリドを、摂取対象の全脂質エネルギー摂取量の1〜95%kcalに相当する量で対象に摂取させる、上記[1]〜[4]のいずれかに記載の組成物および用剤。
[6]長鎖脂肪酸グリセリドをさらに含んでなる、上記[1]〜[5]のいずれかに記載の組成物および用剤。
[7]組成物中の中鎖脂肪酸グリセリドと長鎖脂肪酸グリセリドとの比率(質量比、固形分換算)が、1:0.1〜1.5である、上記[6]に記載の組成物および用剤。
[8]タンパク質および/または糖質をさらに含んでなる、上記[1]〜[7]のいずれかに記載の組成物および用剤。
[9]中鎖脂肪酸グリセリドおよび長鎖脂肪酸グリセリドの合計質量の、タンパク質および糖質の合計質量に対する比率(質量比、固形分換算)が、0.1以上である、上記[8]に記載の組成物および用剤。
[10]組成物中の中鎖脂肪酸グリセリド、長鎖脂肪酸グリセリド、タンパク質および糖質の含有量が、組成物全体のエネルギーに対してそれぞれ30〜90%kcal、5〜50%kcal、0〜15%kcalおよび0〜10%kcalである、上記[8]または[9]に記載の組成物および用剤。
[11]中鎖脂肪酸グリセリドが、中鎖脂肪酸トリグリセリドである、上記[1]〜[10]のいずれかに記載の組成物および用剤。
[12]長鎖脂肪酸グリセリドが、長鎖脂肪酸トリグリセリドである、上記[6]〜[11]のいずれかに記載の組成物。
[13]食品組成物である、上記[1]〜[12]のいずれかに記載の組成物および用剤。
[14]栄養組成物である、上記[1]〜[13]のいずれかに記載の組成物および用剤。
[15]油脂代替物である、上記[1]〜[13]のいずれかに記載の組成物および用剤。
[16]炭素数8の飽和脂肪酸を構成脂肪酸として含む中鎖脂肪酸グリセリドを有効成分として含んでなる、肥満症の治療、予防または改善用組成物および肥満症の治療剤、予防剤または改善剤。
[17]炭素数8の飽和脂肪酸を構成脂肪酸として含む中鎖脂肪酸グリセリドを有効成分として含んでなる、肥満症の発症リスクの低減用組成物および肥満症の発症リスクの低減剤。
本発明の組成物および用剤は、本発明の中鎖脂肪酸グリセリド以外の脂肪酸グリセリドとして長鎖脂肪酸グリセリドをさらに含んでいてもよい。「長鎖脂肪酸グリセリド」は、長鎖脂肪酸とグリセロールがエステル結合した構造を有する化合物であり、グリセロールに長鎖脂肪酸が1つ結合した長鎖脂肪酸モノグリセリド、グリセロールに長鎖脂肪酸が2つ結合した長鎖脂肪酸ジグリセリド、グリセロールに長鎖脂肪酸が3つ結合した長鎖脂肪酸トリグリセリドが含まれる。長鎖脂肪酸グリセリドは、好ましくは長鎖脂肪酸トリグリセリド(LCT: Long Chain Triglyceride、本明細書において「LCT」ということがある)である。以下、長鎖脂肪酸グリセリドに関する記載は、本発明の好ましい態様において、長鎖脂肪酸トリグリセリドに関する記載として読み替えることができる。
本発明の組成物および用剤は、タンパク質をさらに含んでいてもよい。本発明の組成物および用剤に使用するタンパク質としては、特に制限されないが、例えば、コーングルテン、小麦グルテン、大豆タンパク質、小麦タンパク質、乳タンパク質、食肉又は魚肉から得られる動物性タンパク質(コラーゲンを含む)、卵白、卵黄が挙げられるが、乳タンパク質が好ましい。乳タンパク質は、ヒト、サル、ゴリラ、マントヒヒ、チンパンジー等の霊長動物や、ウマ、ウシ、スイギュウ、ヒツジ、ヤギ、ブタ、ラクダ、シカ等の家畜動物、イヌ、ネコ等の愛玩動物等の哺乳動物から得られる乳に含まれるタンパク質成分を使用することができ、好ましくはホエイタンパク質や、カゼインおよびその塩である。
本発明の組成物および用剤は、糖質をさらに含んでいてもよい。糖質は、食物繊維ではない炭水化物であって、単糖類、二糖類、オリゴ糖および多糖類を含む。単糖類としては、グルコース(ブドウ糖)、フルクトース(果糖)、ガラクトース等が挙げられる。二糖類としては、マルトース(麦芽糖)、スクロース(ショ糖)、ラクトース(乳糖)等が挙げられる。オリゴ糖としては、ガラクトオリゴ糖、フラクトオリゴ糖、マンナンオリゴ糖等が挙げられる。多糖類としては、デンプン(アミロース、アミロペクチン)、グリコーゲン、デキストリン等が挙げられる。なお、ここで、糖質は、ラクトースを含むのが好ましく、ラクトースを含むがグルコースを含まないのがより好ましく、実質的にラクトースのみを含むのがさらに好ましい。
<質量比>
中鎖脂肪酸グリセリド:10〜80質量%(好ましくは20〜60質量%)
長鎖脂肪酸グリセリド:1〜45質量%(好ましくは10〜42質量%)
タンパク質:0〜30質量%(好ましくは5〜25質量%)
糖質:0〜15質量%(好ましくは3〜13質量%)
<エネルギー比>
中鎖脂肪酸グリセリド:30〜90%kcal(好ましくは40〜70%kcal)
長鎖脂肪酸グリセリド:5〜50%kcal(好ましくは20〜48%kcal)
タンパク質:0〜15%kcal(好ましくは3〜12%kcal)
糖質:0〜10%kcal(好ましくは2〜8%kcal)
・体脂肪が気になる方へ
・内臓脂肪が気になる方へ
・体重が気になる方へ
・太り気味の方へ
・肥満が気になる方へ
・おなかの脂肪を減らすのを助ける
・ウエスト周囲径を減らすのを助ける
・BMI値の改善に役立つ
(1)試験方法
7週齢の雄性C57BL/6Jマウス(日本エスエルシー社)をCLEA Rodent Diet CE−2(日本クレア社製)にて1週間馴化した後、5群(n=9または10)に分け、表1および表2に示した組成の飼料、すなわち、4種類の試験食および通常食のいずれかを5週間与えた。具体的には、試験食として、AIN−93G標準組成飼料をもとに作製した低炭水化物高脂肪食飼料にMCTおよびLCTを配合したMCT食と、AIN−93G標準組成飼料をもとに作製した低炭水化物高脂肪食飼料にMCTを配合せずにLCT(和光純薬社製)のみを配合したLCT食を調製した。
結果は図1〜3に示される通りであった。なお、試験期間中の試験食摂取量およびエネルギー摂取量は試験群間に有意な差は見られなかった(データ示さず)。
Claims (17)
- 炭素数8の飽和脂肪酸を構成脂肪酸として含む中鎖脂肪酸グリセリドを有効成分として含んでなる、脂肪蓄積抑制用、体重増加抑制用および/またはケトン体生成促進用組成物。
- 前記中鎖脂肪酸グリセリドの中鎖脂肪酸総量に対する炭素数8の飽和脂肪酸量の比率(質量比、固形分換算)が、0.6以上である、請求項1に記載の組成物。
- 前記中鎖脂肪酸グリセリドが、炭素数10の飽和脂肪酸および/または炭素数12の飽和脂肪酸を構成脂肪酸としてさらに含む、請求項1または2に記載の組成物。
- 前記中鎖脂肪酸グリセリドを、1日当たり3g以上(固形分換算)の量で対象に摂取させる、請求項1〜3のいずれか一項に記載の組成物。
- 前記中鎖脂肪酸グリセリドを、摂取対象の全脂質エネルギー摂取量の1〜95%kcalに相当する量で対象に摂取させる、請求項1〜4のいずれか一項に記載の組成物。
- 長鎖脂肪酸グリセリドをさらに含んでなる、請求項1〜5のいずれか一項に記載の組成物。
- 組成物中の中鎖脂肪酸グリセリドと長鎖脂肪酸グリセリドとの比率(質量比、固形分換算)が、1:0.1〜1.5である、請求項6に記載の組成物。
- タンパク質および/または糖質をさらに含んでなる、請求項1〜7のいずれか一項に記載の組成物。
- 中鎖脂肪酸グリセリドおよび長鎖脂肪酸グリセリドの合計質量の、タンパク質および糖質の合計質量に対する比率(質量比、固形分換算)が、0.1以上である、請求項8に記載の組成物。
- 組成物中の中鎖脂肪酸グリセリド、長鎖脂肪酸グリセリド、タンパク質および糖質の含有量が、組成物全体のエネルギーに対してそれぞれ30〜90%kcal、5〜50%kcal、0〜15%kcalおよび0〜10%kcalである、請求項8または9に記載の組成物。
- 中鎖脂肪酸グリセリドが、中鎖脂肪酸トリグリセリドである、請求項1〜10のいずれか一項に記載の組成物。
- 長鎖脂肪酸グリセリドが、長鎖脂肪酸トリグリセリドである、請求項6〜11のいずれか一項に記載の組成物。
- 食品組成物である、請求項1〜12のいずれか一項に記載の組成物。
- 栄養組成物である、請求項1〜13のいずれか一項に記載の組成物。
- 油脂代替物である、請求項1〜13のいずれか一項に記載の組成物。
- 炭素数8の飽和脂肪酸を構成脂肪酸として含む中鎖脂肪酸グリセリドを有効成分として含んでなる、肥満症の治療、予防または改善用組成物。
- 炭素数8の飽和脂肪酸を構成脂肪酸として含む中鎖脂肪酸グリセリドを有効成分として含んでなる、肥満症の発症リスクの低減用組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018126545A JP2020005504A (ja) | 2018-07-03 | 2018-07-03 | 脂肪蓄積抑制用組成物 |
US17/256,785 US20210260015A1 (en) | 2018-07-03 | 2019-07-02 | Composition for inhibiting fat accumulation |
PCT/JP2019/026313 WO2020009111A1 (ja) | 2018-07-03 | 2019-07-02 | 脂肪蓄積抑制用組成物 |
CN201980043748.0A CN112399799A (zh) | 2018-07-03 | 2019-07-02 | 脂肪蓄积抑制用组合物 |
TW108123263A TW202015670A (zh) | 2018-07-03 | 2019-07-02 | 抑制脂肪蓄積之組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018126545A JP2020005504A (ja) | 2018-07-03 | 2018-07-03 | 脂肪蓄積抑制用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020005504A true JP2020005504A (ja) | 2020-01-16 |
Family
ID=69060373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018126545A Pending JP2020005504A (ja) | 2018-07-03 | 2018-07-03 | 脂肪蓄積抑制用組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210260015A1 (ja) |
JP (1) | JP2020005504A (ja) |
CN (1) | CN112399799A (ja) |
TW (1) | TW202015670A (ja) |
WO (1) | WO2020009111A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7224008B1 (ja) | 2022-08-30 | 2023-02-17 | 株式会社東洋新薬 | 経口組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110353101A (zh) * | 2019-07-30 | 2019-10-22 | 广州市优百特饲料科技有限公司 | 一种猪用脂肪粉及其制备方法和用途 |
EP4317452A1 (en) * | 2021-03-22 | 2024-02-07 | The Nisshin Oillio Group, Ltd. | Screening method for glp-1 secretion control agent, glp-1 secretion control agent, composition for preventing or ameliorating diabetes, obesity, postpranidal hyperglycemia, neurodegenerative disease, hypoglycemia, adiposity, or nesidioblastosis, method for promoting secretion of glp-1 in gpr84-expressing cells, method for producing composition for promoting secretion of glp-1, use of gpr84 agonist for producing therapeutic agent for disease, glp-1 secretion promotion agent, and composition for oral ingestion |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022049A1 (ja) * | 2002-09-05 | 2004-03-18 | The Nisshin Oillio Group, Ltd. | 痩身剤およびその飲食物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4568585B2 (ja) * | 2003-11-18 | 2010-10-27 | 花王株式会社 | 油脂組成物 |
KR100635863B1 (ko) * | 2004-12-07 | 2006-10-18 | 주식회사 신동방 | 기능성 혼합 유지 조성물 |
JP2017046688A (ja) * | 2015-08-31 | 2017-03-09 | 株式会社みやぎヘルスイノベーション | 体重増加抑制用飲料組成物 |
-
2018
- 2018-07-03 JP JP2018126545A patent/JP2020005504A/ja active Pending
-
2019
- 2019-07-02 US US17/256,785 patent/US20210260015A1/en not_active Abandoned
- 2019-07-02 WO PCT/JP2019/026313 patent/WO2020009111A1/ja active Application Filing
- 2019-07-02 CN CN201980043748.0A patent/CN112399799A/zh active Pending
- 2019-07-02 TW TW108123263A patent/TW202015670A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022049A1 (ja) * | 2002-09-05 | 2004-03-18 | The Nisshin Oillio Group, Ltd. | 痩身剤およびその飲食物 |
Non-Patent Citations (2)
Title |
---|
CURR DEV NUTR 2017;1:1-5, JPN6023000065, ISSN: 0005097710 * |
NUTRITION AND METABOLISM 2009,6:31, JPN6023000064, ISSN: 0005097711 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7224008B1 (ja) | 2022-08-30 | 2023-02-17 | 株式会社東洋新薬 | 経口組成物 |
JP2024033053A (ja) * | 2022-08-30 | 2024-03-13 | 株式会社東洋新薬 | 経口組成物 |
Also Published As
Publication number | Publication date |
---|---|
TW202015670A (zh) | 2020-05-01 |
WO2020009111A1 (ja) | 2020-01-09 |
US20210260015A1 (en) | 2021-08-26 |
CN112399799A (zh) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6609555B2 (ja) | 脳機能改善剤、及び認知機能障害の予防または治療剤 | |
TW201036618A (en) | Nutritional composition for controlling blood sugar level | |
WO2020009111A1 (ja) | 脂肪蓄積抑制用組成物 | |
WO2008120797A1 (ja) | Ampk活性化剤 | |
JP2007254440A (ja) | 脂質代謝調節剤及び脂質代謝調節食品 | |
JP5749880B2 (ja) | D−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤 | |
JPWO2007114499A1 (ja) | 抗脂肪蓄積用組成物 | |
JP2010222284A (ja) | 血中gip上昇抑制剤 | |
JP2003113089A (ja) | 脂質蓄積性阻害およびコレステロール低下作用を有するキトサン含有製剤および飲食品 | |
JP2022159178A (ja) | 抗老化用組成物 | |
JP2008074794A (ja) | 肥満予防又は改善剤 | |
JP2021185197A (ja) | 食後脂質燃焼促進剤 | |
JP2021151267A (ja) | 脂質燃焼促進剤 | |
WO2019181822A1 (ja) | エネルギー代謝促進用組成物 | |
WO2019139032A1 (ja) | 癌患者筋肉量減少抑制組成物 | |
JP7383874B2 (ja) | エンドトキシンの血中移行阻害用組成物 | |
JPH10262607A (ja) | 乳幼児用栄養組成物 | |
WO2020158852A1 (ja) | ケトン体産生促進用組成物 | |
JP2012188426A (ja) | 脂質代謝改善用組成物 | |
JP6596185B2 (ja) | 総ケトン体濃度上昇剤、油脂組成物、医薬組成物、食品組成物 | |
WO2022255284A1 (ja) | 妊婦用経口投与剤 | |
JP2000302677A (ja) | カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物 | |
WO2018074415A1 (ja) | たんぱく質効率向上用の組成物 | |
JP2016074617A (ja) | 脂肪蓄積抑制剤 | |
JP5008910B2 (ja) | 脂質代謝改善用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230704 |